Veru Dirección

Dirección controles de criterios 3/4

El CEO de Veru's es Mitch Steiner , nombrado en Oct 2016, tiene una permanencia de 7.5 años. compensación anual total es $4.71M, compuesta por 18.4% salario y 81.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 5.01% de las acciones de la empresa, por valor de €9.01M. La antigüedad media del equipo directivo y de la junta directiva es de 5.6 años y 3.3 años, respectivamente.

Información clave

Mitch Steiner

Chief Executive Officer (CEO)

US$4.7m

Compensación total

Porcentaje del salario del CEO	18.4%
Permanencia del CEO	7.6yrs
Participación del CEO	5.0%
Permanencia media de la dirección	5.7yrs
Promedio de permanencia en la Junta Directiva	3.4yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Mitch Steiner en comparación con los beneficios de Veru?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$39m
Dec 31 2023	n/a	n/a	-US$63m
Sep 30 2023	US$5m	US$866k	-US$93m
Jun 30 2023	n/a	n/a	-US$125m
Mar 31 2023	n/a	n/a	-US$141m
Dec 31 2022	n/a	n/a	-US$116m
Sep 30 2022	US$6m	US$761k	-US$84m
Jun 30 2022	n/a	n/a	-US$47m
Mar 31 2022	n/a	n/a	-US$28m
Dec 31 2021	n/a	n/a	-US$16m
Sep 30 2021	US$2m	US$618k	US$7m
Jun 30 2021	n/a	n/a	-US$144k
Mar 31 2021	n/a	n/a	-US$476k
Dec 31 2020	n/a	n/a	US$2m
Sep 30 2020	US$1m	US$502k	-US$19m
Jun 30 2020	n/a	n/a	-US$10m
Mar 31 2020	n/a	n/a	-US$10m
Dec 31 2019	n/a	n/a	-US$13m
Sep 30 2019	US$800k	US$392k	-US$12m
Jun 30 2019	n/a	n/a	-US$17m
Mar 31 2019	n/a	n/a	-US$22m
Dec 31 2018	n/a	n/a	-US$22m
Sep 30 2018	US$740k	US$383k	-US$24m
Jun 30 2018	n/a	n/a	-US$21m
Mar 31 2018	n/a	n/a	-US$14m
Dec 31 2017	n/a	n/a	-US$11m
Sep 30 2017	US$831k	US$406k	-US$9m

Compensación vs. Mercado: La compensación total de Mitch($USD4.71M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD702.03K).

Compensación vs. Ingresos: La compensación de Mitch ha sido consistente con los resultados de la empresa en el último año.

CEO

Mitch Steiner (62 yo)

7.6yrs

Permanencia

US$4,714,041

Compensación

Dr. Mitchell S. Steiner, also known as Mitch, M.D., F.A.C.S, has been the Chief Executive Officer, President and Director at Veru Inc. (formerly known as The Female Health Company) since October 31, 2016 &...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Mitchell Steiner	Chairman	7.6yrs	US$4.71m	5.01% $ 9.0m
Harry Fisch	Vice Chairman & Chief Corporate Officer	7.6yrs	sin datos	5.47% $ 9.8m
Michele Greco	CFO & Chief Administrative Officer	6.4yrs	US$1.55m	0.066% $ 118.2k
K. Barnette	Chief Scientific Officer	5.7yrs	US$1.69m	0% $ 0
Samuel Fisch	Executive Director of Investor Relations & Corporate Communications	5.1yrs	sin datos	sin datos
Michael Purvis	Executive VP	3.2yrs	sin datos	sin datos
Kevin Gilbert	Executive Vice President of Corporate Development	7.3yrs	sin datos	sin datos
Martin Tayler	Executive Vice President of FC2 Global Operations	no data	US$193.01k	sin datos
Philip Greenberg	Executive VP & Deputy General Counsel	3.3yrs	sin datos	sin datos
Domingo Rodriguez	Executive Vice President of Global Clinical Operations	6.1yrs	sin datos	sin datos
Gary Bird	Executive Vice President of Quality & Regulatory Affairs	5.3yrs	sin datos	sin datos
Jason Davies	Executive VP and GM of UK	1.8yrs	sin datos	sin datos

5.7yrs

Permanencia media

61.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de FMW es experimentado (5.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Mitchell Steiner	Chairman	7.6yrs	US$4.71m	5.01% $ 9.0m
Harry Fisch	Vice Chairman & Chief Corporate Officer	7.6yrs	sin datos	5.47% $ 9.8m
Louis Aronne	Chief Medical Advisor & Member of the Scientific Advisory	less than a year	sin datos	sin datos
David D. Ho	Chairman of Scientific Advisory Board	1.3yrs	sin datos	sin datos
Andrew Love	Board Observer	7.6yrs	sin datos	sin datos
Robert Schooley	Member of the Scientific Advisory Board	less than a year	sin datos	sin datos
Michael Rankowitz	Independent Director	6.2yrs	US$875.93k	0.068% $ 122.9k
Xiaoqin Lu	Independent Director	3yrs	US$835.75k	0.0067% $ 12.0k
Caroline Apovian	Member of Scientific Advisory Board	less than a year	sin datos	sin datos
Mario Eisenberger	Independent Director	7.6yrs	US$795.57k	0% $ 0
Grace Hyun	Independent Director	3.8yrs	US$755.39k	0.010% $ 18.2k
Erik Swenson	Member of the Scientific Advisory Board	less than a year	sin datos	sin datos

3.4yrs

Permanencia media

65yo

Promedio de edad

Junta con experiencia: La junta directiva de FMW se considera experimentada (3.3 años de antigüedad promedio).

Veru Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Veru Inc. Appoints Louis Aronne as Chief Medical Advisor and A Member of the Scientific Advisory Board

Veru Inc. Announces New Scientific Advisory Board for Its Enobosarm Program for High Quality Weight Loss

Veru Inc., Annual General Meeting, Mar 26, 2024

High number of new and inexperienced directors

Veru Announces Executive Appointments

Veru Inc., Annual General Meeting, Mar 28, 2023

Recent updates

Veru Inc. to Report Q2, 2024 Results on May 08, 2024

Veru Inc. Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Veru Inc. Appoints Louis Aronne as Chief Medical Advisor and A Member of the Scientific Advisory Board

Veru Receives a Notification Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Veru Inc. Announces New Scientific Advisory Board for Its Enobosarm Program for High Quality Weight Loss

Veru Inc. announced delayed 10-Q filing

Veru Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug Application for its Phase 2b Clinical Study

Veru Receives Non-Compliance Notice From Nasdaq

Veru Inc., Annual General Meeting, Mar 26, 2024

Veru Inc. to Report Q1, 2024 Results on Feb 08, 2024

Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with Glp-1 Drugs for Weight Loss

New major risk - Shareholder dilution

Veru Inc. has completed a Follow-on Equity Offering in the amount of $33 million.

Veru Inc. has completed a Follow-on Equity Offering in the amount of $33 million.

Third quarter 2023 earnings released: US$0.075 loss per share (vs US$0.28 loss in 3Q 2022)

Veru Inc. Reports Muscle Data from 5 Clinical Studies of Enobosarm

Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication

Veru Inc. Announces Clinical Data from Its Discontinued Phase 3 ARTEST Clinical Trial of Enobosarm Monotherapy

New major risk - Financial position

Third quarter 2023 earnings released: EPS: US$0.072 (vs US$0.28 loss in 3Q 2022)

New minor risk - Market cap size

Veru Inc. to Report Q3, 2023 Results on Aug 10, 2023

High number of new and inexperienced directors

Veru Inc.(NasdaqCM:VERU) dropped from Russell 2000 Dynamic Index

Veru Announces Executive Appointments

Second quarter 2023 earnings released: US$0.48 loss per share (vs US$0.18 loss in 2Q 2022)

Veru Inc. announced that it expects to receive $100 million in funding from Lincoln Park Capital, LLC

Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS

First quarter 2023 earnings released: US$0.46 loss per share (vs US$0.08 loss in 1Q 2022)

Veru Inc., Annual General Meeting, Mar 28, 2023

Veru Inc. to Report Q1, 2023 Results on Feb 09, 2023

Bragar Eagel & Squire, P.C. Announces Class Action Lawsuit Against Veru Inc

Veru Inc. Appoints David D. Ho as Chairman of Its Scientific Advisory Board

Wolf Haldenstein Adler Freeman & Herz LLP Announces Securities Class Action Lawsuit Against Veru Inc

Full year 2022 earnings released: US$1.05 loss per share (vs US$0.097 profit in FY 2021)

Veru Inc. Provides Update on FDA Advisory Committee Meeting Regarding Emergency Use Authorization of Sabizabulin to Treat Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome

Veru Inc. Announces Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with Covid-19 on Supplemental Oxygen At Infectious Disease Week 2022

Veru Inc. to Present Late-Breaker Oral Presentation of Sabizabulin Treatment for Hospitalized Adults with Covid-19 on Supplemental Oxygen At Infectious Disease Week 2022

Veru Inc. Receives Expedited Provisional Registration Regulatory Pathway for Sabizabulin Treatment in Hospitalized COVID-19 Patients by Australia’s Therapeutic Goods Administration

Veru Inc. Appoints Jason Davies as Executive Vice President General Manager of Europe, the Middle East and Africa, Latin America, and Asia Pacific

Third quarter 2022 earnings released: US$0.28 loss per share (vs US$0.034 loss in 3Q 2021)

Veru Inc. to Report Q3, 2022 Results on Aug 11, 2022

Uk’S Medicines and Healthcare Products Regulatory Agency (Mhra) Supports Expedited Review of Marketing Authorization Application for Sabizabulin Treatment in Hospitalized Covid-19 Patients of Veru Inc

Veru Announces New England Journal of Medicine Evidence Publication of Phase 3 Clinical Trial Results Demonstrating That Sabizabulin Treatment Significantly Reduced Deaths in High-Risk Hospitalized Covid-19 Patients

Veru Submits Emergency Use Authorization Application to U.S. FDA for Sabizabulin, Its Novel, Oral Antiviral and Anti-Inflammatory Drug Candidate for Hospitalized COVID-19 Patients At High Risk for ARDS

Veru Announces Presentation of Final Positive Phase 1b/2 Clinical Trial Results for Sabizabulin in Metastatic Castration Resistant Prostate Cancer at the 2022 American Society of Clinical Oncology Annual Meeting

Veru Inc. Appoints Joel Batten as Executive Vice President and Head of Its U.S. Infectious Disease Franchise, Effective May 23, 2022

Second quarter 2022 earnings released: US$0.18 loss per share (vs US$0.038 loss in 2Q 2021)

FDA Has Grants Veru Inc.'s Pre-Emergency Use Authorization (EUA) Meeting Date for Positive Sabizabulin Phase 3 COVID-19 Study

Veru Inc. Announces Results from Randomized Placebo-Controlled Phase 2 Study of Oral Sabizabulin

Veru Inc.'s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study

Veru Inc. Announces the Presentation of Updated Data from the Phase 1B/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer At the 2022 ASCO Genitourinary Cancers Symposium

Veru Inc. Reports That Independent Data Monitoring Committee for the Phase 3 Sabizabulin COVID-19 Clinical Study Recommends Continuing Study as Planned

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment improved over the past week

Veru Inc. Announces FDA Grant of Fast Track Designation for Sabizabulin for the Treatment of Hospitalized COVID-19 Patients At High Risk for Acute Respiratory Distress Syndrome

Veru Inc., Annual General Meeting, Mar 29, 2022

Veru Inc., Annual General Meeting, Mar 29, 2022

Investor sentiment improved over the past week

Veru Inc. Announces FDA Grant of Fast Track Designation for Enobosarm for the Treatment of AR+ ER+ HER2- Metastatic Breast Cancer

Veru Inc. Announces FDA Approval of ENTADFI

Veru Inc. Announces Presentation of Preclinical Evidence Supporting the Therapeutic Benefit of Enobosarm Alone or in Synergistic Combination with a CDK4/6 Inhibitor Against Palbociclib Resistant Metastatic Breast Cancer at the 2021 San Antonio Breast Cancer Symposium

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

No longer forecast to breakeven

Forecast to breakeven in 2021

Veru Announces Positive Updated Data from Phase 1B/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer

Third quarter 2021 earnings released: US$0.034 loss per share (vs US$0.045 loss in 3Q 2020)

Veru Inc. Announces Enrolls First Patient in Phase 3 Veracity Clinical Trial of Sabizabulin in Metastatic Castration Resistant and Androgen Receptor Targeting Agent Resistant Prostate Cancer

Vice Chairman & Chief Corporate Officer recently sold €689k worth of stock